Filing Details
- Accession Number:
- 0001209191-20-049162
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-02 16:42:41
- Reporting Period:
- 2020-08-31
- Accepted Time:
- 2020-09-02 16:42:41
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1679082 | Myovant Sciences Ltd. | MYOV | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1714080 | Camilo Juan Ferreira Arjona | C/O Myovant Sciences Inc. 2000 Sierra Point Parkway, 9Th Floor Brisbane CA 94005 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2020-08-31 | 11,307 | $7.78 | 149,333 | No | 4 | M | Direct | |
Common Shares | Disposition | 2020-08-31 | 11,307 | $20.01 | 138,026 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Stock Option (Right to Buy) | Disposition | 2020-08-31 | 11,307 | $0.00 | 11,307 | $7.78 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
231,267 | 2027-08-14 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 trading plan.
- The shares were sold at prices ranging from $20.00 to $20.03. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.